Results 81 to 90 of about 464 (144)
Steroid‐responsive generalised sterile necrotising pyogranulomatous lymphadenitis in a cat
Journal of Small Animal Practice, Volume 66, Issue 9, Page 670-675, September 2025.A 1.5‐year‐old neutered male cat was presented with fever, inappetence, lethargy and marked generalised lymphadenopathy of 4 days duration. Excisional biopsy of peripheral lymph nodes revealed necrotising pyogranulomatous lymphadenitis. Extensive investigation failed to identify an underlying infectious [bacterial (Bartonella, Mycobacteria, Mycoplasma,
L. Lecot +4 more
wiley +1 more source
Menrath ulcers in cats: four cases (2014‐2023)
Journal of Small Animal Practice, Volume 66, Issue 5, Page 346-352, May 2025.Objectives To report the clinical presentation, treatment and outcomes of four cats diagnosed with Menrath ulcers causing significant oral haemorrhage. Materials and Methods For all cats, data on signalment, history, physical examination, treatment and outcomes were collected by reviewing medical records.
K. Whybrow, T. Hernon, M. Pilot
wiley +1 more source
Characterization and Polymorphism Analysis of Lotilaner (CREDELIO) for Flea and Tick Treatment in Dogs [PDF]
CREDELIO (Lotilaner) is a beef-flavored chewable tablet for oral administration to dogs and puppies based on their weight. Each chewable tablet provides a minimum dose of 9 mg of lotilaner per pound of body weight (20 mg/kg)
Anonymous,
core +1 more source
Comparative analysis of isoxazoline activity on human and canine GABA receptors expressed in Xenopus oocytes. [PDF]
Parasit VectorsBackground Isoxazolines, including sarolaner, lotilaner, afoxolaner and fluralaner, are a class of ectoparasiticides that target gamma-aminobutyric acid receptors (GABARs) in insects and acari.
Sager H, Sarr A, Kuntz E, Rufener L.
europepmc +2 more sources
, 2023 Abstract Background This study aimed to evaluate lotilaner (Credeli®)’s larvicidal efficacy in the treatment of dogs naturally infested with Dermatobia hominis larvae.Methods A total of 12 dogs that naturally presented at least three live D. hominis larvae were medicated.
Rafaella Tortoriello +3 more
openaire +1 more source
Comprehensive evaluation of lifespan‐extending molecules in C. elegans
Aging Cell, Volume 24, Issue 4, April 2025.We evaluated 16 of the most frequently reported lifespan‐extending molecules in C. elegans, examining their effects on lifespan with live and UV‐killed OP50. We assessed the compounds' impact on bacterial growth, and their effects on various nematode strains.
Grace B. Phelps +6 more
wiley +1 more source
Environmental Toxicity Of Isoxazoline Drugs On Non-Target Species [PDF]
, 2023 Lyme disease affects tens of thousands of people every year in the United States, causing serious illness and even death. It is caused by the bacterium, Borrelia burgdorferi, through infected black-legged tick bites. The range of these ticks is expanding,
Cooper, Haley M
core +1 more source
Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review
British Journal of Pharmacology, Volume 181, Issue 11, Page 1553-1575, June 2024.Abstract In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer.
Andreas Papapetropoulos +16 more
wiley +1 more source
Parasites & Vectors, 2021 Background A randomised, blinded, positive controlled, multicentre, Good Clinical Practice-compliant, pivotal field study was conducted to evaluate the effectiveness and safety of a new combination of lotilaner + milbemycin oxime tablets (Credelio® Plus;
Brad Hayes +2 more
doaj +1 more source
Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis
Ophthalmology, 2023 Ian Benjamin Gaddie +14 more
openaire +1 more source